Clinical trial

Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

Novartis PharmaceuticalsActive, not recruitingStarted Jul 10, 2023106 enrolledNCT05776888

Abstract

This non-interventional study aims to observe the effect of early versus late Ofatumumab treatment in RMS patients in a real-world setting in Austria over an observational period of 24 months.

Keywords

relapsing multiple sclerosisRMSOfatumumabNISRelapsing Multiple Sclerosis

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.